Abstract |
The space adaptation syndrome is one of the more vexing problems confronted by our nation's astronauts during their journeys. This syndrome may be a variant of motion sickness, although this possibility has been questioned. Physostigmine, a centrally active cholinesterase inhibitor which increases brain acetylcholine, was found to cause a motion sickness-like syndrome--in psychiatric patients and normals--including nausea, emesis, malaise, dysphoria, increases in serum ACTH, beta-endorphin, cortisol, and prolactin, Neostigmine, a non-centrally acting cholinesterase inhibitor, and saline placebo caused no such effects. The above effects closely parallel those of motion sickness. Thus, the effects of physostigmine may be a convenient model for screening for treatments for motion sickness or space adaptation syndrome, or for predicting who will develop these syndromes.
|
Authors | D S Janowsky, S C Risch, M Ziegler, B Kennedy, L Huey |
Journal | Aviation, space, and environmental medicine
(Aviat Space Environ Med)
Vol. 55
Issue 8
Pg. 692-6
(Aug 1984)
ISSN: 0095-6562 [Print] United States |
PMID | 6487203
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Catecholamines
- Hormones
- Physostigmine
|
Topics |
- Adaptation, Physiological
(drug effects)
- Adolescent
- Adult
- Behavior
(drug effects)
- Blood Pressure
(drug effects)
- Catecholamines
(blood)
- Hormones
(blood)
- Humans
- Male
- Middle Aged
- Motion Sickness
(chemically induced)
- Nausea
(chemically induced)
- Physostigmine
(pharmacology)
- Pulse
(drug effects)
- Space Flight
- Syndrome
|